​As of April 15, 2021, changes were made to the availability of certain drugs through our Direct Ship Drug Program. We expanded the program to include several enzyme replacement therapies, antineoplastic drugs, alpha-1 proteinase inhibitors, and immunological agents, as well as a variety of miscellaneous infusible therapeutics.

To learn more about the drugs that have been added or removed from the program, please read our announcement article.

The updated drug list can be found on the Direct Ship Drug Program webpage.